Summary During carcinogenesis. pancreatic acinar cells can dedifferentiate into ductal adenocarcinoma of the pancreas. DSL-6AIC1 cells represent an in vitro model of this carcinogenic sequence. This study was designed to examine the effects of retinoids on cell growth in DSL-6A/C1 cells and to characterize further the molecular mechanisms underlying the antiproliferative actions of retinoids. Treatment of DSL-6A/C1 cells with retinoids results in a time-and dose-dependent inhibition of cell growth, paralleled by a retinoid-mediated transactivation of a pTK::]RAREx2-luciferase reporter construct transientty transfected into DSL-6A/C1 cells. Retinoid receptor expression was evaluated by reverse transcriptase polymerase chain reaction (RT-PCR) using subtype-specific primers and demonstrated expression of retinoic acid receptor alpha (RAR-a), RAR-I and retinoid X receptor alpha (RXR-a). Using a panel of receptor subtype-specific agonists, the RAR-a specific agonist Ro 40-6055 was the most potent retinoid in terms of growth inhibition. Furthermore, all-trans-retinoic acid-mediated growth inhibition and transactivation was completely blocked by the RAR-a-speciflc antagonist Ro 41-5253. In summary, the RAR-a subtype predominantly mediates the antiproliferative effects of retinoids in DSL-6AJC1 cells. Furthermore, this cell system provides a feasible tool to study the molecular mechanisms underlying the growth inhibitory effects of retinoids in ductal pancreatic carcinoma cells derived from a primary acinar cell phenotype.
Keywords: ductal pancreatic carcinoma: all-trans-retinoic acid: retinoic acid receptor a Despite intensive clinical trials durinn the last decades. therapy of advanced human exocrine pancreatic carcinoma remains unsatisfactory: onl1 few chemo-and radiochemotherapeutic regimen have produced modest surxix al benefits in patients with advanced disease (Lionetto et al. 1995) . Therefore. alternative treatment strategies have focused on substances which exert their antitumorigenic effects by growth inhibition and induction of cellular differentiation. rather than cvtotoxicitv. In this context. retinoids have recently emerged as a novel therapeutic strategy for the treatment of human pancreatic carcinoma (Rosewicz et al. 1995a : Brembeck et al. 1998 . Previous studies were performed using cultured human ductal pancreatic carcinoma cell lines. because more than 90% of human pancreatic cancers are histoloaicallv classified as ductal adenocarcinoma of the exocrine pancreas. How-ever. the pathogenesis of pancreatic cancer remains unsolved. especiallx regarding the cell type of oriain (acinar versus duct cell) as the primary progenitor of the carcinogenic pathway. A carcinogen-induced model in the Syrian golden hamster results in primary ductal pancreatic carcinoma. harbouring a point mutation at codon 12 of the K-ras gene. as is characteristicallv observed in the majority of human tumours (Cerny et al. 1990 ): other animal models of pancreatic carcinoma suggest that this malianancv is probably not derived from a primarn duct cell origin because it lnfektiologie). Hindenburgdamm 30. D-12200 Berlin. Germany could be demonstrated that acinar cells upon malignant transformation can dedifferentiate to a duct-like cell type in some rodents (rats and mice) w ithout aquisition of K-ras point mutations (Dissin et al. 1975 : Longnecker and Curphey. 1975 : Bockman et al. 1976 . 1978 : Satake et al. 1984 : Scarpelli et al. 1984 : De Lisle and Logsdon. 1990 : Longnecker et al. 1992 : Pettengill et al. 1993 . As an in -itro model for this 'transdifferentiation' theory of pancreatic carcinogenesis. Pettengill et al (1993) established the DSL-6A/C 1 cell line from an azaserine-induced acinar carcinoma of the rat and obtained a cell line w ith duct cell-specific properties by regrafting the tumour cells from in vivo to in vitro and vice versa. Althourh not experimentally proven. it appears conceivable that this carcinogenic sequence might also apply for human pancreatic carcinoma aiven that more than 90% of the human exocrine pancreas is represented by acinar cells. Therefore. the aim of our study was to establish this cell line as a suitable in vitro model to investigate the molecular mechanisms involved in retinoidmediated growth inhibition.
Retinoids. which are summarized as natural and synthetic derivatiN-es of vitamin A. have been demonstrated to inhibit proliferation and induce differentiation in a variety of malignant tissues (Lotan. 1980 : Bollag. 1983 : Lotan et al. 1990 : Love and Gudas. 1994 . Clinical trials demonstrated beneficial effects of retinoids in the treatment of X arious premalignant lesions and malig'nancies (reviewed by Bollag and Holdener. 1992 : Smith et al. 1992 : Tallman and Wiernik. 1992 . The molecular action of retinoids was partially elucidated within the past decade. After passive diffusion through the cell membrane. retinoids interact wvith two cytoplasmic retinoid-binding proteins. which are believed to reaulate intracellular retinoid homeostasis (GIauere. 1994) . Retinoids 1288 exert their pleiotropic effects on cell growth and differentiation via tx%&o families of nuclear retinoid receptors: the retinoic acid receptors (RAR) and the retinoid X receptors (RXR) (Umesono. 1991 : Gigu&re. 1994 . Each retinoid receptor family consists of three different subtypes (Ct. . y) encoded by distinct aenes (Mangelsdorf et al. 1994) . The RAR subtypes can further be divided in multiple isoforms because of gene transcription via different use of two internal promoter sites or. alternatively. by different splicing of the mRNA transcripts (Kastner et al. 1990 : Zelent et al. 1991 : Giguere. 1994 ). The distinct receptor subtypes are expressed in a cell type-specific pattern during embryogenesis.
in the adult organism as well as in malignant tissues. It has therefore been concluded that retinoid sensitivity of a given tissue is defined in part through the expression pattern of RARIRXR subtypes (Gigaure. 1994).
RARs are bound and activated by the naturally occurring retinoid all-trans-retinoic acid (Leid et al. 1992a : Gigaure. 1994 ). In contrast. RXRs are predominantly activated by 9-cis-retinoic acid (Heyman et al. 1992 : Leid et al. 1992b . whereas ATRA does not bind to these receptors (Leid et al. 1992a ). In addition. retinoid receptors interact with a Xvariety of co-activators and co-repressors. thereby either relieving repression by the basal transcription machinery or inducing ligand-dependent transcription above the basal level (Mangelsdorf and Chambon. 1995 Cell culture Cells were grown under 95% air and 5%7 carbon dioxide at 37-C as subconfluent monolayers in DMEM or RPMI-1640 supplemented with either 20% v/v (AR42J) or 10% v/v (Dan-G and DSL-6A/C 1) FCS. penicillin (100U ml-') and streptomycin (100 tgc ml-'). All experiments were carried out in the log phase of growth after the cells were seeded for 24 h. Preparation of retinoids as stock solutions was performed under subdued light and aliquots were kept at -80'C for a maximum of 4 weeks. DMSO was used as a solvent for all retinoids. Control cells were treated with the same amount of DMSO and the final concentration of DMSO in the culture medium did not exceed 0.1% c (v/v) Cell viability in growth assays was routinely checked by trypan blue staining and was routinely found to be >95%7.
RNA isolation and Northem blot analysis
Total RNA was isolated using the RNAzol reagent (WAK Chemie Medical. Bad Homburg. Germany) according to the instructions of the manufacturer. Qualitative analysis of RNA was perforned using Northem blot analysis as previously described (Rosewicz et al. 1994) . RNA was denatured in a buffer containgno 6% s/v formaldehyde and 5% v/v formamide. subjected to electrophoretic separation in a 1% agarose gel containing formaldehyde and then transferred to a nylon membrane. A RNA ladder was electrophoresed in parallel for size determination. The cDNA probes for synaptophysin (Rosewicz et al. 1992a) . human carbonic anhydrase II (Rosewicz et al. 1995b ) and amylase (Rosewicz et al. 1989) have been previously described. The cDNA inserts were eluted by galasmilk with the Geneclean H kit (Dianova. Hamburg. Germany).
cDNA probes were radioactively labelled with [a 'P]dC`TP using the random primer labelling kit following the instructions provided by the supplier. Unincorporated nucleotides were removed by passing the reaction sample through a Sephadex G50 (LKB Pharmacia. Bromma. Sweden) column. The specific activity of the probes was usually 1-2 x 109 c.p.m. pg-' DNA. RESULTS DSL-6A/C1 express duct cell-specific markers
To verify the ductal phenotype of DSL-6A/Cl cells, we initially examined the expression of cell type-specific markers in two wellcharacterized pancreatic carcinoma cell lines, AR42J and Dan-G, and compared them with DSL-6A/Cl cells. We have previously described the AR42J cell line as an amphicrine pancreatic carcinoma cell line, which combines exocrine acinar with neuroendocrine features (Rosewicz et al, 1992b) . The ductal phenotype of Dan-G cells has previously been confirmed by cytokeratin phenotyping (Rosewicz et al, 1995a) . Using a cDNA for the pancreatic acinar cell-specific human amylase in Northern blot analysis, we detected a single hybridization band with a molecular size of 1.8 kb only in AR42J cells, but not in Dan-G or in DSL-6A/C1 cells (Figure 1 ). Hybridization with a cDNA probe for the neuroendocrine vesicle membrane-specific protein synaptophysin reveals a hybridization signal of approximately 2.8 kb only in AR42J cells, but could not be detected in Dan-G or in DSL-6A/C1 cells ( Figure  1 ). Using a human cDNA probe for carbonic anhydrase II (CAII), which is specifically expressed in pancreatic duct cells, we obtained a hybridization signal of about 2.0 kb both in Dan-G cells and in DSL-6A/Cl cells, but not in AR42J cells (Figure 1) . Therefore, DSL-6A/Cl cells, although derived from a pancreatic acinar carcinoma, fail to express pancreatic acinar and neuroendocrine markers, but do express CAII -a marker gene specifically restricted to duct cells of the pancreas (Kim et al, 1990 ).
Effects of all-trans-retinoic acid on cell growth and transactivation of a RARE reporter construct in DSL-6AIC1 cells
As an initial attempt to determine the responsiveness of a dedifferentiated pancreatic acinar cell line to the antiproliferative effects of retinoids, we examined the effects of the naturally occurring retinoid all-trans-retinoic acid (ATRA) on anchorage-dependent growth in DSL-6A/C cells. We incubated DSL-6A/Cl cells with ATRA over a period of 4 days and determined cell number every 24 h. For initial experiments, we chose 10 gM ATRA because this represents the concentration which can be achieved after oral uptake of this substance at maximal, non-toxic plasma levels in humans (Muindi et al, 1992) . After incubation with ATRA, we observed a significant time-dependent growth inhibition in DSL-6A/C1 cells as early as 2 days (74.9±7.4% of control, n = 3, P < 0.05; Figure 2) . Furthermore, the antiproliferative effects of ATRA are dose dependent, with half-maximal growth inhibition observed at 100 nM ATRA (77.5±10.8% of control, n = 6, P < 0.05) and maximal inhibition at 10 gM ATRA (55.7 ± 7.6% of control, n = 6, P < 0,05; Figure 3A Figure  3B ). These data demonstrate that incubation of DSL-6A/Cl cells British Joumal of Cancer (1998) 
Effects of retinoid analogues on proliferation of DSL-6A/C1 cells
We next asked which nuclear retinoid receptor family might be responsible for the ATRA-mediated growth inhibition and transcriptional control of retinoid responsive genes in DSL-6A/C1 cells. We therefore compared the effects of the retinoid analogues ATRA, 13-cis-and 9-cis-RA on anchorage-dependent growth. Figure 4 demonstrates the dose-dependent retinoid effects on anchorage-dependent growth of DSL-6A/C1 cells. Maximal antiproliferative effects could be observed with 10 ,M of each retinoid analogue. The biological activity of these retinoids on an equimolar basis (at 10 gM 120 h-') in DSL-6A/C1 is as follows:
ATRA > 13-cis-RA > 9-cis-RA. At lower concentrations (<1 gM), only 13-cis-RA and ATRA exerted similar growth inhibitory effects, whereas 9-cis-RA failed to demonstrate a significant growth inhibition (Figure 4) . Although isomerization and degradation have to be considered, these observations suggest that retinoid-mediated growth inhibition in DSL-6A/C1 cells might be due to activation of the RAR receptor family rather than the RXR pathway. Figure 5 ). The validity of the primers for rat tissues has previously been described (Rosewicz et al, 1995a) .
To exclude amplification signals arising from contaminating genomic DNA, each PCR was initially performed without prior reverse transcriptase reaction and repeatedly found to be negative. Using the receptor subtype-specific primers we detected expression of RAR-a, RAR-P and RXR-a, whereas no amplification signal for RAR-y, RXR-P and RXR-y could be detected (Figure 5 (1998) 78(10) retinoid Ro 40-6055 and the RAR-f-specific agonist Ro 48-2249. Both agonists have been shown to bind and activate preferentially the corresponding receptor subtype (Crettaz et al, 1990) . The antiproliferative effects of the RAR-a-specific agonist were comparable to the growth-inhibitory effects of ATRA on an equimolar basis: 00 nm Ro 40-6055 (RAR-a specific agonist) 77.0±3.1% of control (n = 3, P < 0.05; Figure 6 ) versus 100 nM ATRA 76.2±3.3% of control (n = 3, P < 0.05; Figure 6 ). In contrast, the RAR-j-specific retinoid Ro 48-2249 was mainly ineffective.
Effects of the RAR-a-specific antagonist Ro 41-5253 on ATRA-mediated growth inhibition and transactivation To further substantiate the role of the RAR-a receptor subtype in mediating the effects of ATRA in DSL-6AIC 1 cells, we used the RAR-a-specific antagonist Ro 41-5253 in growth and transactivation assays. This retinoid has been shown to revert, selectively, RAR-a-mediated retinoid effects (Apfel et al, 1992) . Incubation of DSL-6AICl cells with this antagonist at the maximal concentration used in our experiments had no effect on growth (data not shown). However, ATRA-mediated growth inhibition can be blocked by the RAR-a-specific antagonist Ro 41-5253 in a dose-dependent manner, with a complete growth inhibition observed at an antagonist concentration of 1-10 ,UM ( Figure 7A ). Similar effects could also be observed when we investigated ATRA-mediated transactivation of the pTK::4RAREx2-luc reporter construct in transiently transfected DSL-6A/C 1 cells: incubation with 1O,M RAR-aspecific antagonist Ro 41-5253 completely blocks the stimulation of luciferase activity induced by 100 nM ATRA (Figure 7 B ).
DISCUSSION
Retinoids have been shown to exert profound effects on cellular growth and differentiation in a variety of malignant cells in vitro and in vivo (Lotan, 1980; Bollag, 1983; Lotan et al, 1990) . Moreover, retinoids have been proven clinically beneficial in certain premalignant lesions (e.g. dysplasias of the cervix, the respiratory tract, in the head and neck area) and in various malignancies (for review see Bollag and Holdener, 1992) . We have previously shown that retinoids induce cellular differentiation and inhibit proliferation of human ductal carcinoma cells in vitro and in vivo (Rosewicz et al, 1995a) . In addition, combination therapy of retinoic acid with interferon a in patients with advanced, unresectable carcinoma of the pancreas results in prolonged survival of responsive patients (Brembeck et al, 1998) . However, the molecular basis of retinoid action in pancreatic carcinoma cells is still incompletely understood, especially with regard to which retinoid receptor subtype might account for the antiproliferative effects of retinoids.
To further dissect this problem, we therefore decided to investigate the molecular effects of retinoids in the pancreatic carcinoma cell line DSL-6A/C 1, because this cell system provides the unique features of a primary acinar pancreatic carcinoma which has dedifferentiated into a ductal phenotype (Pettengill et al, 1993) . Some experimental evidence suggests that, at least in some rodents, this sequence of malignant transformation might best reflect the in vivo situation of pancreatic carcinogenesis (Dissin et al, 1975; Longnecker and Curphey, 1975; Bockman et al, 1976 Bockman et al, , 1978 Satake et al, 1984; Scarpelli et al, 1984; De Lisle and Logsdon, 1990; Longnecker et al, 1992) .
The ductal phenotype of DSL-6A/C1 cells was confirmed by characterizing the expression pattern of pancreatic cell typespecific marker genes compared with two other well-defined pancreatic carcinoma cell lines, Dan-G and AR42J. Dan-G cells represent a retinoid-sensitive, human ductal pancreatic carcinoma cell line (Rosewicz et al, 1995a) . AR42J cells were established from an azaserine-treated rat model and represent a retinoid-insensitive, acinar pancreatic carcinoma cell line with neuroendocrine features (Rosewicz et al, 1992b (Rosewicz et al, , 1995a Somewhat less pronounced growth inhibitory effects were observed for the stereoisomer of ATRA. 13-cis-RA. whereas the retinoid analogue 9-cis-RA failed to inhibit cell growth at lower. therapeutically relevant concentrations (<100 nrm). These results indicate that retinoid-mediated growth inhibition is mainly due to activation of the RAR receptor family because ATRA predominantly activates the RAR subtypes (Heyman et al. 1992 : Leid et al. 1992a : Giguere. 1994 ).
We next focused on the molecular basis of ATRA-mediated effects in DSL-6A/C I cells and tested the ability of ATRA to stimulate gene transcription of a synthetic RARE reporter construct.
In transient transfection assays with the pTK::PRAREx2-luc construct. we demonstrated that ATRA dose-dependently mediates transactivation of this reporter construct. The dose-response curve of ATRA-mediated transactivation correlates tightly with the growth inhibitory effects observed in the anchorage-dependent growth assays. These data are compatible with the hypothesis that antiproliferative effects of retinoids are mediated by the transcriptional control of genes regulating cellular growth. However. it should be kept in mind that the effects of retinoids might also be mediated by transcriptional repression as well as functional interference with the transcription factor AP-1 (Giguere. 1994) .
To achieve further insight into the molecular mechanism of retinoid action in this cell system. we characterized the expression of the RAR and RXR subtypes. To our surprise. we found a very restricted expression pattern of RAR/RXR subtypes in DSL-6A/C I cells. Using the highly sensitive RT-PCR technique. we detected two RAR subtypes (RAR-a and RAR-() and only one member of the RXR family (RXR-a). RAR-y. RXR-0 and RXR-y are not expressed in these cells. The lack of RXR-y expression is not surprising because this subtype exhibits a very restricted expression pattern in only a few tissues (Dolle et al. 1990) . and is also not expressed in a broad panel of human pancreatic carcinoma cell lines (Rosewicz et al. 1995a) . In contrast to the DSL-6A/C1 cells. all previously characterized human ductal pancreatic carcinoma cell lines express the RAR-y as well as the RXR-, (Rosewicz et al. 1995a ). The retinoid-insensitive rat amphicrine carcinoma cell line AR42J shows, similar to the retinoid-sensitive DSL-6A/C1 cells. no expression of the RAR-y. The selective loss of the RAR-y subtype might be due to the malignant transformation of acinar cells because this receptor subtype is expressed in normal pancreatic acinar cells (Xu et al. 1996) .
Each receptor subtype might fulfill a distinct biological function in a given cell by activating a panel of responsive genes (Giguere. 1994) . We therefore investigated which receptor subtype might be responsible for ATRA-mediated growth inhibition in DSL-6AIC 1 cells. Because ATRA predominantly activates the RAR subtypes and DSL-6AIC1 cells only express RAR-a and RAR-0. we investigated the effects of two RAR subtype-specific retinoids on anchorage-dependent growth: Ro 40-6055, a specific agonist of the RAR-a subtype: and Ro 48-2249. a RAR-P specific agonist (Crettaz et al. 1990 ). Only the RAR-a specific agonist exerted dose-dependent antiproliferative effects similar to equimolar concentrations of ATRA. whereas the RAR-(-specific retinoid Ro 48-2249 had no antiproliferative effects at concentrations less than I gm. This suggests an important role for the RAR-a subtype in mediating the effects of ATRA in DSL-6A/C 1 cells.
If the RAR-a subtype is responsible for growth inhibition and transactivation of the RARE reporter construct in DSL-6A/C1 cells, it should be possible to block the ATRA-mediated effects by antagonizing the RAR-a subtype. To test this hypothesis. we used the highly specific RAR-a antagonist Ro 41-5253 (Apfel et al. 1992) in anchorage-dependent growth and transactivation assays. ATRA-mediated growth inhibition as well as transactivation of the RARE reporter construct could be completely blocked by the RAR-a antagonist. suggesting that RAR-a is crucial for mediating the biological effects of ATRA in DSL-6AC1 cells.
Recent studies indicated that the expression pattem of distinct retinoid receptor subtypes determines retinoid-mediated effects in a given tissue (Giguere. 1994) . For example. RAR-a is found to be responsible for growth inhibition in breast cancer cells (van der Leede et al. 1995) . whereas RAR-1 mediates antiproliferative effects in fibroblasts (Lee et al. 1992 ) and RAR-yis predominantly responsible for growth inhibition by retinoids in human teratocarcinoma (Moasser et al. 1994) or neuroblastoma (Marshall et al. 1995) . Despite this divergence in different tissues. the identification of a distinct receptor subtype mediating the antiproliferative effects of retinoids in a given cell type provides a powerful therapeutic tool to potentiate the antiproliferative effects and minimize side-effects potentially mediated by other receptor subtypes.
Based on the different retinoid receptor expression pattern between rat and human pancreatic carcinoma cells. the implications of this study for experimental therapy of human pancreatic cancer have to be interpreted cautiously. However. the results of the present study are indicative that receptor subtype-specific retinoids (i.e. RAR-a-specific agonists) might be an attractive alternative to all-trans-retinoic acid in the experimental treatment of pancreatic carcinoma.
In summary, we have demonstrated that the antiproliferative effects of retinoids in the ductal pancreatic carcinoma cell line DSL-6A/C I are predominantly mediated by the RAR-a subtype. Moreover. DSL-6A/C 1 cells as a model of ductal adenocarcinoma derived from dedifferentiated pancreatic acinar cells provide a feasible in vitro system to study the molecular mechanisms underlying growth inhibitory effects of retinoids in ductal pancreatic carcinoma cells.
